Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq to Delist BG Medicine’s Stock

NEW YORK (GenomeWeb) – BG Medicine said today that its common stock will be delisted from Nasdaq effective at the opening of the Dec. 4, 2015 trading session.

The company was unable to maintain compliance with listing requirements for the exchange.

BG was notified on March 10, 2015 that its stock no longer qualified for listing on the exchange because it did not have a minimum bid price of at least $1 per share, and the company’s stockholder’s equity was not at least $2.5 million.

BG was allowed to continue listing on the exchange as it worked towards regaining compliance, though it was unable to do so. On Sept. 14, 2015, Nasdaq issued a final delisting determination, notifying BG that trading of its stock would be suspended on Sept.16, 2015.

BG did not request a review of this decision, and the decision became final on Oct. 29, 2015.

The company’s stock is now listed on the OTC market.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.